APA (7th ed.) Citation

Blauvelt, A., Kircik, L., Schlesinger, T., Pierce, E., Burge, R., Behling, M., . . . Armstrong, A. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: Pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Blauvelt, Andrew, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, and April Armstrong. Lebrikizumab Is Associated with Improvements in Patient-reported Symptoms and Quality-of-life Measures Across Eczema Area and Severity Index Response Categories: Pooled Results from Phase-3 Randomized ADvocate1 and ADvocate2 Studies in Patients with Moderate-to-severe Atopic Dermatitis. Taylor & Francis Group.

MLA (9th ed.) Citation

Blauvelt, Andrew, et al. Lebrikizumab Is Associated with Improvements in Patient-reported Symptoms and Quality-of-life Measures Across Eczema Area and Severity Index Response Categories: Pooled Results from Phase-3 Randomized ADvocate1 and ADvocate2 Studies in Patients with Moderate-to-severe Atopic Dermatitis. Taylor & Francis Group.